Phase I evaluation of erlotinib and docetaxel with concomitant boost radiation for locoregionally advanced squamous cell carcinoma of the head and neck

Trial Profile

Phase I evaluation of erlotinib and docetaxel with concomitant boost radiation for locoregionally advanced squamous cell carcinoma of the head and neck

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Nov 2014

At a glance

  • Drugs Docetaxel (Primary) ; Erlotinib (Primary)
  • Indications Head and neck cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Apr 2011 Planned End Date changed from 1 Dec 2010 to 1 Oct 2012, according to the ClinicalTrials.gov record.
    • 02 Feb 2010 Planned end date changed from 1 Apr 2010 to 1 Dec 2010 as reported by ClinicalTrials.gov.
    • 09 Jun 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top